Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;23(5):318-331.
doi: 10.1038/s41579-024-01121-2. Epub 2024 Nov 21.

Hepatitis B and D virus entry

Affiliations
Review

Hepatitis B and D virus entry

Koichi Watashi et al. Nat Rev Microbiol. 2025 May.

Abstract

Hepatitis B virus (HBV) entry is the initial step of viral infection, leading to the formation of covalently closed circular DNA, which is a molecular reservoir of viral persistence and a key obstacle for HBV cure. The restricted entry of HBV into specific cell types determines the nature of HBV, which has a narrow host range in tissues and species. Hepatitis D virus (HDV) shares viral surface antigens with HBV and thus follows a similar entry mechanism at its early stages. In late 2012, sodium taurocholate cotransporting polypeptide was discovered as an HBV and HDV entry receptor. Since then, the mechanisms of HBV and HDV entry have been extensively analysed. These analyses have expanded our understanding of HBV and HDV host tropism and have provided new strategies for the development of antiviral agents. Notably, the structures of sodium taurocholate cotransporting polypeptide and its interaction with the 2-48 amino acid region of viral preS1 have been recently solved. These findings will stimulate further entry studies. In this Review, we summarize current understanding of HBV and HDV entry and future perspectives.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. World Health Organization. Global hepatitis report 2024. https://www.who.int/publications/i/item/9789240091672 (2024).
    1. Lampertico, P., Degasperi, E., Sandmann, L., Wedemeyer, H. & Delta Cure Working Group. Hepatitis D virus infection: pathophysiology, epidemiology and treatment. Report from the First International Delta Cure Meeting 2022. JHEP Rep. 5, 100818 (2023). - PubMed - PMC - DOI
    1. Kramvis, A. et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat. Rev. Gastroenterol. Hepatol. 19, 727–745 (2022). - PubMed - PMC - DOI
    1. Tsukuda, S. & Watashi, K. Hepatitis B virus biology and life cycle. Antivir. Res. 182, 104925 (2020). - PubMed - DOI
    1. Weng, M. K. et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb. Mortal Wkly Rep. 71, 477–483 (2022). - PubMed - PMC - DOI

MeSH terms

Substances

LinkOut - more resources